(Q37989160)

26 August 2017

title

Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma (English)

1 reference

26 August 2017

0 references

Adrian M. Di Bisceglie

3

object named as

Adrian M Di Bisceglie

1 reference

26 August 2017

Robert G Gish

1

1 reference

26 August 2017

Riccardo Lencioni

2

1 reference

26 August 2017

Jean-Luc Raoul

4

1 reference

26 August 2017

Vincenzo Mazzaferro

5

1 reference

26 August 2017

publication date

1 April 2012

1 reference

Expert Review of Gastroenterology & Hepatology

26 August 2017

published in

1 reference

26 August 2017

volume

6

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

173-185

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Primary liver cancer: worldwide incidence and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Prevalence of hepatocellular carcinoma and relation to cirrhosis: comparison of two different cities of the world--Trieste, Italy, and Chiba, Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Management of chronic hepatitis C in veterans: the potential of integrated care models

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Multidisciplinary management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Current strategy for staging and treatment: the BCLC update and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Randomized clinical trials in hepatocellular carcinoma and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Sorafenib: a review of its use in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Sorafenib: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

New considerations for an overall approach to treat hepatocellular carcinoma in cirrhotic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Laparoscopic liver resection for subcapsular hepatocellular carcinoma complicating chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Prognosis of hepatocellular carcinoma: the BCLC staging classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Analysis of 6381 hepatocellular carcinoma patients in southern Taiwan: prognostic features, treatment outcome, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Understanding surgical decision making in early hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Review article: the management of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

CT and MRI of hepatocellular carcinoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Radiofrequency ablation and chemoembolization for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Loco-regional treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Percutaneous ablation of hepatocellular carcinoma: current status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Transcatheter and ablative therapeutic approaches for solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Hepatocellular carcinoma with extrahepatic collateral arterial supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Yttrium-90 microspheres for the treatment of hepatocellular carcinoma: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Intra-arterial injection of iodine-131-labeled lipiodol for treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Prognostic markers and putative therapeutic targets for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Radiotherapy for painful bone metastases from hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FEGH.11.105

21 January 2018

Identifiers

DOI

10.1586/EGH.11.105

1 reference

26 August 2017

1 reference